A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 112 participants.
Also called NCT03657095
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 112 participants
- Sponsor
- Lung Biotechnology PBC
- Registry
-
NCT03657095
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Israel
- Registry status
- Terminated
Technical summary
Registry record NCT03657095. Non-randomized; no masking; primary purpose treatment. Start 2018-12-10 (actual); primary completion 2019-07-20 (actual). Results posted on 2020-09-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
- Acronym
- BEAT OLE
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Esuberaprost
- Intervention (Drug)
- Placebo
- Lead sponsor
- Lung Biotechnology PBC
Record details
- Record id
cardio:ct-nct03657095- Content hash
5da27e69c82978baf483d25623fb838c983845fb7eaddbe9108d8d57a099129c